康惠製藥(603139.SH):擬以3000萬元受讓科萊維藥業10.71%股權 並向其增資521.33萬元
格隆匯12月10日丨康惠製藥(603139.SH)公佈,公司擬以人民幣3000萬元受讓泰灃合夥持有湖北科萊維生物藥業有限公司(“科萊維藥業”或“目標公司”)10.7143%的股權,同時以人民幣3958萬元認購目標公司521.328066萬元新增註冊資本.
本次交易完成後,目標公司註冊資本將由2771.618626萬元變更為3292.9467萬元,公司將合計持有目標公司40%的股權。
湖北科萊維生物藥業有限公司系公司的參股子公司,公司持有其18%的股權。西安泰灃醫藥投資合夥企業(有限合夥)(“泰灃合夥”、“股權轉讓方”)持有目標公司10.7143%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.